Mirum Pharmaceuticals, Inc.
MIRM
Rankning i aktier
#3257
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aktiekurs
$83.66
Marknadsvärde
$5.43B
Förändring (1 dag)
0.26%
Förändring (1 år)
20.20%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
Aktiekurshistorik för Mirum Pharmaceuticals, Inc. (MIRM)
Högsta slutkurs: $82.38 den 2026-10-01
Lägsta slutkurs: $13.66 den 2019-07-01
Lägsta slutkurs: $13.66 den 2019-07-01
Aktiekurshistorik för Mirum Pharmaceuticals, Inc. från 2019 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 28.86% |
| 2025 | 68.24% |
| 2024 | 35.06% |
| 2023 | 73.09% |
| 2022 | 24.19% |
| 2021 | -29.47% |
| 2020 | 29.71% |
| 2019 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.02 | 25.70% |
US
|
|
| $221.69 | 725.66% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.57 | 7.66% |
NL
|
